18558765. INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS simplified abstract (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM)
Contents
INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS
Organization Name
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventor(s)
Stanton Mchardy of San Antonio TX (US)
Michael W. Tidwell of San Antonio TX (US)
Andrew J. Brenner of San Antonio TX (US)
Ratna K. Vadlamudi of San Antonio TX (US)
INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18558765 titled 'INDANONE AND TETRALONEKETO OR HYDROXYL OXIMES AS CANCEL THERAPEUTICS
The abstract of this patent application describes compounds, salts, stereoisomers, and prodrugs that are ER ligands, with a focus on ERβ selectivity and specificity.
- These compounds are designed to target specific estrogen receptors, providing potential therapeutic benefits.
- The innovation lies in the development of compounds that selectively target ERβ, which could lead to more effective treatments with fewer side effects.
- The patent covers a range of compounds and their derivatives that show promise as ER ligands for various applications.
Potential Applications: - Treatment of hormone-related conditions such as breast cancer or osteoporosis - Development of new pharmaceuticals targeting estrogen receptors
Problems Solved: - Addressing the need for more selective and effective estrogen receptor modulators - Improving the treatment options for hormone-related diseases
Benefits: - Enhanced therapeutic efficacy with reduced side effects - Potential for personalized medicine based on estrogen receptor profiles
Commercial Applications: Title: "Innovative ER Ligands for Targeted Therapies in Hormone-Related Diseases" This technology could have significant implications in the pharmaceutical industry, leading to the development of novel treatments for hormone-related conditions.
Questions about ER Ligands: 1. How do ER ligands differ from traditional hormone therapies?
ER ligands target specific estrogen receptors, providing more targeted effects compared to broad-spectrum hormone therapies.
2. What potential challenges could arise in the development of ERβ-selective ligands?
Developing compounds that are both selective and effective can be a complex process, requiring careful optimization and testing.
Original Abstract Submitted
Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ERβ selective and/or ERβ specific ligands.
- BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Stanton Mchardy of San Antonio TX (US)
- Michael W. Tidwell of San Antonio TX (US)
- Andrew J. Brenner of San Antonio TX (US)
- Ratna K. Vadlamudi of San Antonio TX (US)
- C07C251/44
- A61P35/00
- C07C311/16
- C07C311/32
- C07D231/56
- C07D239/34
- C07D257/04
- C07D317/50
- CPC C07C251/44